Ignite Creation Date:
2024-05-06 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 2:17 PM
Study NCT ID:
NCT05110482
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2023-06-06
First Post:
2021-09-28
Brief Title:
Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients Undergoing Caesarean Section
Sponsor:
Cairo University
Organization:
Cairo University
Study Overview
Official Title:
Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients With Stenotic Valvular Heart Disease Undergoing Caesarean Section
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Postpartum hemorrhage PPH is the primary cause of nearly one quarter of all maternal deaths globally Management of uterine tone after delivery involves giving a prophylactic uterotonic and the use of controlled cord traction to facilitate delivery of the placenta and minimize blood loss Syntocinon and carbetocin are the most commonly used drugs During caesarean delivery of stenotic valvular disease patient the anesthesiologist have an important question what is the best drug used for prevention of PPH with minimal hemodynamic effect regarding Systemic vascular resistance SVR Cardiac out put COPHeart rate HR blood pressure As uterotonic drugs may cause severe hypotension decrease in SVR and COP that may not be tolerated by these patients this thesis aims to compare between syntocinon and carbetocin regarding their effect on cardiac output and systemic vascular resistance using cardiometry in cardiac patients with stenotic lesions during caesarean delivery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None